Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP46A1 | Q9Y6A2 | 3/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 4/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5860204 | 0.90 | CYP2C9 (0.41) | SMN1; SMN2GLATSHRALDH1A1KMT2A | |
| SCHEMBL6095501 | 0.83 | TSHR (0.43) | SMN1; SMN2GLATSHRKDM4EALDH1A1 | |
| SCHEMBL6660693 | 0.83 | CYP2C9 (0.36) | SMN1; SMN2GLATSHRKDM4EALDH1A1 | |
| SCHEMBL5859246 | 0.80 | CYP46A1 (0.49) | CYP46A1SMN1; SMN2KDM4EALDH1A1KMT2A | |
| SCHEMBL5859304 | 0.80 | CYP46A1 (0.43) | CYP46A1SMN1; SMN2GLATSHRKDM4E | |
| SCHEMBL6096412 | 0.80 | TSHR (0.42) | SMN1; SMN2GLATSHRKDM4EALDH1A1 | |
| SCHEMBL5860280 | 0.78 | CYP46A1 (0.42) | CYP46A1SMN1; SMN2GLATSHRKDM4E | |
| SCHEMBL6095933 | 0.77 | SCN9A (0.55) | SMN1; SMN2TSHRALDH1A1KMT2AHTT | |
| SCHEMBL6095989 | 0.75 | GAA (0.39) | CYP46A1SMN1; SMN2TSHRALDH1A1KMT2A | |
| SCHEMBL5859043 | 0.75 | ALDH1A1 (0.46) | TSHRKDM4EALDH1A1KMT2ACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7122543-B2 | Substituted benzoic acid derivatives having NF-κB inhibiting action | DAIICHI SUNTORY PHARMA CO., LTD. (JP) | 2006-10-17 | — | — | US | disclosed |
| EP-1437339-A1 | SUBSTITUTED BENZOIC ACID DERIVATIVES EXHIBITING NF-KAPPA B INHIBITING ACTIVITY | Daiichi Suntory Pharma Co., Ltd. (JP) | 2004-07-14 | — | — | EP | disclosed |
| US-20040039061-A1 | Substituted benzoic acid derivatives exhibiting nf-k b inhibiting activity | DAIICHI ASUBIO PHARMA CO., LTD. (JP) | 2004-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039061-A1 | Substituted benzoic acid derivatives exhibiting nf-k b inhibiting activity | NFKBIA, NFKB2, IKBKB | CYP46A1 709/4885SMN1; SMN2 3711/4885GLA 2250/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.